Heap of medical pills in white, blue and other colors. Pills in plastic package. Panoramic banner for design.
As a pharmacist working in the pharmacy benefit management (PBM) industry, I've witnessed firsthand the transformative impact of biologic drugs, like Humira. (That's the brand name for the version of adalimumab that came to the U.S. market first.)
While these medications have revolutionized treatment for complex diseases like inflammatory conditions, they've also contributed significantly to drug spend for employers and patients.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Sharon Faust
Sharon Faust is the chief pharmacy officer at Navitus, a pharmacy benefit manager. She is a licensed pharmacist in Wisconsin and has a doctor of pharmacy degree. She serves on the board of the National Association of Specialty Pharmacy and the drug selection advisory committee at CivicaScript.
